GS upgrades Sartorius Stedim to 'buy' after share price pullback

Sartorius AG

30/03/2026 09:07

** Goldman Sachs upgrades French lab equipment maker Sartorius Stedim STDM.PA (Stedim) to "buy" from "neutral", saying recent share weakness overpenalises the stock despite resilient underlying biopharma demand

** Broker says the year-to-date pullback, driven by macro and interest rate concerns, means bioprocessing growth is no longer fully reflected in the shares

** GS adds Stedim is largely insulated from broader Life Science sector worries, citing supportive underlying biopharma drivers such as pharma R&D and manufacturing commitments

** Broker keeps a "neutral" rating on Sartorius Group SATG.DE and lowers its PT for Stedim by 9% to 214 euros ($246.16) due to higher interest rate risks

** GS expects recent capital expenditure announcements to support an equipment demand recovery from the second half of 2027, following a stable 2026

** Out of 15 analysts that cover the company, 14 rate the stock "strong buy" or "buy,"​ and one "hold" - LSEG data

($1 = 0.8693 euros)

 (Reporting by Jerome Terroy)

 ((jerome.terroy@thomsonreuters.com))